Cargando…

Real-World Use of Sotrovimab for Pre-Emptive Treatment in High-Risk Hospitalized COVID-19 Patients: An Observational Cross-Sectional Study

Data on use of monoclonal antibodies (mAbs) in hospitalized patients are limited. In this cross-sectional study, we evaluated the use of mAbs for early treatment of unvaccinated hospitalized patients with mild-to-moderate COVID-19. All inpatients at our center were screened on 27 October 2021. Prima...

Descripción completa

Detalles Bibliográficos
Autores principales: Ong, Sean W. X., Ren, Dongdong, Lee, Pei Hua, Sutjipto, Stephanie, Dugan, Christopher, Khoo, Bo Yan, Tay, Jun Xin, Vasoo, Shawn, Young, Barnaby E., Lye, David C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8944709/
https://www.ncbi.nlm.nih.gov/pubmed/35326808
http://dx.doi.org/10.3390/antibiotics11030345
_version_ 1784673786987020288
author Ong, Sean W. X.
Ren, Dongdong
Lee, Pei Hua
Sutjipto, Stephanie
Dugan, Christopher
Khoo, Bo Yan
Tay, Jun Xin
Vasoo, Shawn
Young, Barnaby E.
Lye, David C.
author_facet Ong, Sean W. X.
Ren, Dongdong
Lee, Pei Hua
Sutjipto, Stephanie
Dugan, Christopher
Khoo, Bo Yan
Tay, Jun Xin
Vasoo, Shawn
Young, Barnaby E.
Lye, David C.
author_sort Ong, Sean W. X.
collection PubMed
description Data on use of monoclonal antibodies (mAbs) in hospitalized patients are limited. In this cross-sectional study, we evaluated the use of mAbs for early treatment of unvaccinated hospitalized patients with mild-to-moderate COVID-19. All inpatients at our center were screened on 27 October 2021. Primary outcome was in-hospital deterioration as defined by a composite of oxygen requirement, intensive care unit (ICU) admission, or mortality within 28 days of admission. Ninety-four out of 410 COVID-19 inpatients were included in the final analysis, of whom 19 (20.2%) received early treatment with sotrovimab. The median age was 73 years (IQR 61–83), and 35 (37.2%) were female. Although the treatment group was significantly older and had more comorbidities, there was a lower proportion of progression to oxygen requirement (31.6% vs. 54.7%), ICU admission (10.5% vs. 24.0%), or mortality (5.3% vs. 13.3%). Kaplan–Meier curves showed a significant difference in time to in-hospital deterioration (log-rank test, p = 0.043). Cox proportional hazards model for in-hospital deterioration showed that sotrovimab treatment was protective (hazard ratio, 0.41; 95% CI, 0.17–0.99; p = 0.047) after adjustment for baseline ISARIC deterioration score. Our findings support the use of sotrovimab for early treatment in hospitalized patients with mild-to-moderate COVID-19 at a high risk of disease progression.
format Online
Article
Text
id pubmed-8944709
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-89447092022-03-25 Real-World Use of Sotrovimab for Pre-Emptive Treatment in High-Risk Hospitalized COVID-19 Patients: An Observational Cross-Sectional Study Ong, Sean W. X. Ren, Dongdong Lee, Pei Hua Sutjipto, Stephanie Dugan, Christopher Khoo, Bo Yan Tay, Jun Xin Vasoo, Shawn Young, Barnaby E. Lye, David C. Antibiotics (Basel) Article Data on use of monoclonal antibodies (mAbs) in hospitalized patients are limited. In this cross-sectional study, we evaluated the use of mAbs for early treatment of unvaccinated hospitalized patients with mild-to-moderate COVID-19. All inpatients at our center were screened on 27 October 2021. Primary outcome was in-hospital deterioration as defined by a composite of oxygen requirement, intensive care unit (ICU) admission, or mortality within 28 days of admission. Ninety-four out of 410 COVID-19 inpatients were included in the final analysis, of whom 19 (20.2%) received early treatment with sotrovimab. The median age was 73 years (IQR 61–83), and 35 (37.2%) were female. Although the treatment group was significantly older and had more comorbidities, there was a lower proportion of progression to oxygen requirement (31.6% vs. 54.7%), ICU admission (10.5% vs. 24.0%), or mortality (5.3% vs. 13.3%). Kaplan–Meier curves showed a significant difference in time to in-hospital deterioration (log-rank test, p = 0.043). Cox proportional hazards model for in-hospital deterioration showed that sotrovimab treatment was protective (hazard ratio, 0.41; 95% CI, 0.17–0.99; p = 0.047) after adjustment for baseline ISARIC deterioration score. Our findings support the use of sotrovimab for early treatment in hospitalized patients with mild-to-moderate COVID-19 at a high risk of disease progression. MDPI 2022-03-05 /pmc/articles/PMC8944709/ /pubmed/35326808 http://dx.doi.org/10.3390/antibiotics11030345 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Ong, Sean W. X.
Ren, Dongdong
Lee, Pei Hua
Sutjipto, Stephanie
Dugan, Christopher
Khoo, Bo Yan
Tay, Jun Xin
Vasoo, Shawn
Young, Barnaby E.
Lye, David C.
Real-World Use of Sotrovimab for Pre-Emptive Treatment in High-Risk Hospitalized COVID-19 Patients: An Observational Cross-Sectional Study
title Real-World Use of Sotrovimab for Pre-Emptive Treatment in High-Risk Hospitalized COVID-19 Patients: An Observational Cross-Sectional Study
title_full Real-World Use of Sotrovimab for Pre-Emptive Treatment in High-Risk Hospitalized COVID-19 Patients: An Observational Cross-Sectional Study
title_fullStr Real-World Use of Sotrovimab for Pre-Emptive Treatment in High-Risk Hospitalized COVID-19 Patients: An Observational Cross-Sectional Study
title_full_unstemmed Real-World Use of Sotrovimab for Pre-Emptive Treatment in High-Risk Hospitalized COVID-19 Patients: An Observational Cross-Sectional Study
title_short Real-World Use of Sotrovimab for Pre-Emptive Treatment in High-Risk Hospitalized COVID-19 Patients: An Observational Cross-Sectional Study
title_sort real-world use of sotrovimab for pre-emptive treatment in high-risk hospitalized covid-19 patients: an observational cross-sectional study
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8944709/
https://www.ncbi.nlm.nih.gov/pubmed/35326808
http://dx.doi.org/10.3390/antibiotics11030345
work_keys_str_mv AT ongseanwx realworlduseofsotrovimabforpreemptivetreatmentinhighriskhospitalizedcovid19patientsanobservationalcrosssectionalstudy
AT rendongdong realworlduseofsotrovimabforpreemptivetreatmentinhighriskhospitalizedcovid19patientsanobservationalcrosssectionalstudy
AT leepeihua realworlduseofsotrovimabforpreemptivetreatmentinhighriskhospitalizedcovid19patientsanobservationalcrosssectionalstudy
AT sutjiptostephanie realworlduseofsotrovimabforpreemptivetreatmentinhighriskhospitalizedcovid19patientsanobservationalcrosssectionalstudy
AT duganchristopher realworlduseofsotrovimabforpreemptivetreatmentinhighriskhospitalizedcovid19patientsanobservationalcrosssectionalstudy
AT khooboyan realworlduseofsotrovimabforpreemptivetreatmentinhighriskhospitalizedcovid19patientsanobservationalcrosssectionalstudy
AT tayjunxin realworlduseofsotrovimabforpreemptivetreatmentinhighriskhospitalizedcovid19patientsanobservationalcrosssectionalstudy
AT vasooshawn realworlduseofsotrovimabforpreemptivetreatmentinhighriskhospitalizedcovid19patientsanobservationalcrosssectionalstudy
AT youngbarnabye realworlduseofsotrovimabforpreemptivetreatmentinhighriskhospitalizedcovid19patientsanobservationalcrosssectionalstudy
AT lyedavidc realworlduseofsotrovimabforpreemptivetreatmentinhighriskhospitalizedcovid19patientsanobservationalcrosssectionalstudy